Experimental drug shows promise as Alzheimer's target, study says

04/3/2012 | Yahoo!

A study in the Archives of Neurology found the experimental drug bapineuzumab reduces levels of phosphorylated tau in spinal fluid, suggesting it might do the same in the brain and affect tangles associated with Alzheimer's disease. Alzheimer's disease experts who commented on the University of Gothenburg preliminary study said it was too soon to draw any conclusions about whether the drug could stop or even slow the degenerative process of Alzheimer's disease.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA